Manufacturers: Gate2Brain, S.L., Shilpa Biocare Pvt Ltd (CMC/manufacturing partner)
G2B-002 is Gate2Brain's lead oncology candidate, a first-in-class peptide-shuttle therapy that uses the proprietary MiniAp4 peptide platform to deliver SN-38 across the blood-brain barrier for the treatment of aggressive pediatric brain cancers including DIPG and pediatric glioblastoma.
G2B-002 is Gate2Brain's lead oncology candidate, a first-in-class peptide-shuttle therapy that uses the proprietary MiniAp4 peptide platform to deliver SN-38 across the blood-brain barrier for the treatment of aggressive pediatric brain cancers including DIPG and pediatric glioblastoma.
G2B-002 utilizes Gate2Brain's proprietary MiniAp4 peptide shuttle platform to transport SN-38, a potent topoisomerase I inhibitor anticancer agent, across the blood-brain barrier (BBB) directly to brain tumors. Preclinical studies demonstrated up to 100-fold higher brain drug transport compared to conventional approaches in animal models.
G2B-002 is being developed for diffuse intrinsic pontine glioma (DIPG) and pediatric glioblastoma (pGBM), two aggressive childhood brain cancers with limited treatment options. It has received Orphan Drug Designation from both the U.S. FDA and the EMA for these indications. Preclinical activity has also been demonstrated in Ewing sarcoma, rhabdomyosarcoma, and neuroblastoma.
5 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
